Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

(2017) Michela Sica et al.   Journal of Hematology & Oncology

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

(2017) Taku Fukuzawa et al.   Scientific Reports

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study

(2016) Michael Loschi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation

(2016) Markus J. Harder et al.   BLOOD

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

(2016) Xuan Yuan et al.   HAEMATOLOGICA

Small-molecule factor D inhibitors targeting the alternative complement pathway

(2016) Jürgen Maibaum et al.   Nature Chemical Biology

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future

(2016) Antonio M. Risitano et al.   SEMINARS IN IMMUNOLOGY

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

(2016) Xuan Yuan et al.   HAEMATOLOGICA

Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria

(2015) Z. Lin et al.   BLOOD

Guidelines for the diagnosis and management of adult aplastic anaemia

(2015) Sally B. Killick et al.   BRITISH JOURNAL OF HAEMATOLOGY

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention

(2015) Dimitrios C. Mastellos et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Complement

(2015) Juan Carlos Varela et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria

(2014) Antonio M. Risitano et al.   BLOOD

Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria

(2014) David J Araten et al.   Journal of Hematology & Oncology

Genetic Variants in C5 and Poor Response to Eculizumab

(2014) Jun-ichi Nishimura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

(2013) Peter Hillmen et al.   BRITISH JOURNAL OF HAEMATOLOGY

mRNA display: from basic principles to macrocycle drug discovery

(2013) Kristopher Josephson et al.   DRUG DISCOVERY TODAY

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

(2013) T. Rondelli et al.   HAEMATOLOGICA

Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties

(2013) C. Q. Schmidt et al.   JOURNAL OF IMMUNOLOGY

Deficiency in Complement Factor B

(2013) Charlotte Slade et al.   NEW ENGLAND JOURNAL OF MEDICINE

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment

(2012) A. M. Risitano et al.   BLOOD

Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria

(2012) R. P. de Latour et al.   HAEMATOLOGICA

New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties

(2012) Hongchang Qu et al.   IMMUNOBIOLOGY

Complement genetics, deficiencies, and disease associations

(2012) Karine R. Mayilyan   Protein & Cell

Disease-Causing Mutations in Genes of the Complement System

(2011) Søren E. Degn et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases

(2011) M. Fridkis-Hareli et al.   BLOOD

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival

(2011) R. J. Kelly et al.   BLOOD

Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test

(2011) B. Höchsmann et al.   VOX SANGUINIS

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement

(2010) M. A. Lindorfer et al.   BLOOD

Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy

(2010) S. Ram et al.   CLINICAL MICROBIOLOGY REVIEWS

Paroxysmal nocturnal hemoglobinuria and eculizumab

(2010) L. Luzzatto et al.   HAEMATOLOGICA

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

(2010) A. Hill et al.   HAEMATOLOGICA

Paroxysmal Nocturnal Hemoglobinuria — Hemolysis before and after Eculizumab

(2010) Antonio M. Risitano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

(2009) A. M. Risitano et al.   BLOOD

How I treat paroxysmal nocturnal hemoglobinuria

(2009) R. A. Brodsky   BLOOD

Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories

(2008) R. P. de Latour et al.   BLOOD

Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab

(2008) A. M. Risitano et al.   BLOOD